Global ETF Survey Is Live! 600+ ETF Professionals Weigh In. See Results →
Tap into the future of mental health treatment with psychedelic ETFs, offering diversified, long-term growth opportunities in an emerging healthcare sector.


Keep up with what matters in ETFs
Get timely ETF insights, market trends, and top ideas straight to your inbox.
Your newsletter subscriptions with us are subject to ETF Central's Privacy Policy and Terms and Conditions.
As psychedelics gain attention for their potential in revolutionizing mental health treatments, investors are seeking ways to tap into this emerging healthcare sector. Several publicly traded companies provide exposure to the development, research, and distribution of psychedelic compounds for therapeutic purposes. Backed by growing scientific validation and evolving regulations worldwide, psychedelics present a unique opportunity within the expanding healthcare industry.
With 1,790 new products launched by July 2026, choosing is harder than ever. Our Global ETF Survey 2026, built on 620 professional investors and allocators, shows how active, fixed income, options-based and thematic ETFs are reshaping fund selection.
Healthcare and biotech companies specializing in psychedelics focus on developing, researching, and commercializing psychedelic compounds for therapeutic applications, particularly in mental health treatments. These companies are often involved in creating and implementing clinical guidelines and clinical trials aimed at proving the efficacy and safety of substances like psilocybin, MDMA, ketamine, and LSD for conditions such as depression, anxiety, PTSD, and addiction. Their work typically spans drug discovery, pharmaceutical development, and regulatory approval processes. Many of these firms collaborate with research institutions, medical professionals, and regulatory bodies to advance their treatments through clinical phases and eventually bring them to market, where they could offer innovative solutions to unmet mental health needs.
The need for improved mental healthcare is urgent both in the United States and globally. In the U.S., nearly one-third of the 50 million adults with mental health conditions do not receive the treatment they need, partly due to barriers like lack of health insurance and high treatment costs. The U.S. also has one of the highest suicide rates among high-income countries, which has been rising over the past two decades. Globally, around 280 million people suffer from depression, and many countries lack adequate mental health resources, such as a sufficient number of mental health professionals and hospital beds. This disparity in mental healthcare access highlights the need for increased investment and policy reforms to address the growing mental health crisis worldwide.
Investing in the psychedelic market can be challenging due to its early-stage nature, volatility, and regulatory hurdles. Psychedelic ETFs offer a way to mitigate these risks by providing diversified exposure to companies across the ecosystem, including those involved in drug development, clinical treatments, and supporting technologies. Managed by professionals who adjust holdings as the market evolves, ETFs may reduce the impact of setbacks from individual companies. With many firms still facing legal and regulatory barriers, ETFs offer a more efficient and accessible route for investors to tap into the sector. Additionally, some ETFs include international stocks, allowing for a broader, global perspective as the psychedelic industry advances. This diversification helps spread risk while capturing opportunities throughout the industry’s growth.
Although the psychedelic sector is still in its early stages, its long-term potential is significant. Psychedelic investments are suited for investors with a long-term view, as the industry is expected to grow considerably with advances in research and increased public and governmental support. As mental health treatment paradigms evolve, many of these funds have the capability to be well-positioned to deliver strong returns over time.
For investors looking to balance risk and reward in a cutting-edge industry, psychedelic ETFs offer a strategic approach. With professional management, diversified exposure, and the ability to navigate the complexities of a highly regulated market, these funds present an attractive opportunity to participate in the future of mental health treatment.
The opinions expressed in this publication are those of the authors and are subject to change. They do not purport to reflect the opinions or views of ETF Central or its members. ETF central does not guarantee the accuracy, completeness, or reliability of the information provided.
Segments
See all
No specific ETFs were tagged
Latest ETF News
See all ETF newsWhy ETFs Trade at Premiums and Discounts—and Why That Isn't Always a Problem


Exchange-Traded Interval Funds: An Interesting Idea, but What Happens When Markets Get Ugly?


Why Market Makers Quote New ETF Launches Differently From Conversions


From Ballots to Bloodbaths: How Political Surprises Can Rock ETF Markets


The Curious Case of Variable Fees vs. Passbacks


Advantages of ETFs over Mutual Funds1/6
Lower Costs
In this guide, we'll explore the advantages of ETFs over mutual funds, giving you valuable insights into why ETFs have gained significant popularity among investors like yourself.
Leveraged ETFs: Unlocking the Potential for Amplified Returns1/6
Understanding Leveraged ETFs
Explore leveraged ETFs: potential for amplified returns & risks. 5 ETFs to consider across equities, commodities & fixed income.
What is a Leveraged ETF?1/6
Introducing Leveraged and Inverse ETFs
In this guide, we'll dive into the world of leveraged ETFs, exploring their definition, mechanics, potential risks, and rewards.
First Look ETF
First Look ETF: Conventional and Unconventional International ETFs
First Look ETF’s November episode covers record-setting ETF launches and inflows with the NYSE, William Blair’s new active international and emerging markets ETFs, and the launch of the Long Nook Uncommon Compounders ETF (LUNC).

ETF Trends
ETF Industry KPIs November 16, 2026
This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

ETF Trends
ETF Industry KPIs November 9, 2026
This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

ETF Trends
ETF Industry KPIs November 3, 2026
This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.
